UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 49

Sortiert nach

KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab

Annals of oncology, 2008-03, Vol.19 (3), p.508-515

2008

Volltextzugriff (PDF)

Radiological tumor size decrease at week 6 is a potent predictor of outcome in chemorefractory metastatic colorectal cancer treated with cetuximab (BOND trial)

Annals of oncology, 2009-08, Vol.20 (8), p.1375-1382

2009

Volltextzugriff (PDF)

Treatment of patients with newly diagnosed metastatic hormone sensitive prostate cancer (mHSPC) in Belgium: a real world data analysis

Acta clinica belgica (English ed. Online), 2022-11, Vol.77 (6), p.897-905

2022

Volltextzugriff (PDF)

Changes in anticancer treatment plans in patients with solid cancer hospitalized with COVID-19: analysis of the nationwide BSMO-COVID registry providing lessons for the future

ESMO open, 2022-12, Vol.7 (6), p.100610-100610, Article 100610

2022

Volltextzugriff (PDF)

Treatment of Zenker’s diverticulum through a flexible endoscope with a transparent oblique-end hood attached to the tip and a monopolar forceps

Endoscopy, 2007-02, Vol.39 (2), p.137-140

2007

Volltextzugriff (PDF)

6005 PIK3CA, BRAF and KRAS mutations and outcome prediction in chemorefractory metastatic colorectal cancer (mCRC) patients treated with EGFR targeting monoclonal antibodies (MoAbs): results of a European Consortium

European journal of cancer supplements, 2009, Vol.7 (2), p.322-322

2009

Volltextzugriff (PDF)

Malnutrition prevalence in advanced cancer patients in Belgium

Clinical nutrition ESPEN, 2021-12, Vol.46, p.S753-S754

2021

Volltextzugriff (PDF)

92 POSTER Amphiregulin and Epiregulin expression in primary colorectal cancer identifies a subgroup of patients that will respond to EGFR inhibition

European journal of cancer supplements, 2008, Vol.6 (12), p.31-31

2008

Volltextzugriff (PDF)

98 POSTER DUSP4 expression level in colorectal primaries predicts overall survival benefit in Kras wild-type and Kras mutant colorectal cancer after treatment with cetuximab for metastatic disease

European journal of cancer supplements, 2008, Vol.6 (12), p.33-33

2008

Volltextzugriff (PDF)

P19 Levels of amphiregulin and epiregulin expression correlate with overall survival in colorectal cancer treated with cetuximab

European journal of cancer supplements, 2007, Vol.5 (8), p.17-17

2007

Volltextzugriff (PDF)

Potential Biomarkers for Response to Cetuximab in Patients with Metastatic Colorectal Cancer (MCRC). A Hellenic Cooperative Oncology Group Study

Annals of oncology, 2012-09, Vol.23, p.ix213

2012

Volltextzugriff (PDF)

630 - Potential Biomarkers for Response to Cetuximab in Patients with Metastatic Colorectal Cancer (MCRC). A Hellenic Cooperative Oncology Group Study

Annals of oncology, 2012-09, Vol.23, p.ix213-ix213

2012

Volltextzugriff (PDF)

P1.28 Dusp4 Expression as A Marker of Heterogeneous Signaling in Colorectal Cancer Patients

Annals of oncology, 2012-06, Vol.23, p.v20

2012

Volltextzugriff (PDF)

Use of tumor size decrease at 6 weeks (w) to predict response (OR), time to progression (TTP), and survival (OS) in chemorefractory metastatic colorectal cancer (cmCRC) treated with cetuximab (CTX) (BOND trial)

Journal of clinical oncology, 2008-05, Vol.26 (15_suppl), p.4068-4068

2008

Volltextzugriff (PDF)

New insights to gene expression signatures from primary FFPE tumors for the prediction of response to cetuximab in KRAS and BRAF wild-type colorectal cancer (CRC)

Journal of clinical oncology, 2010-05, Vol.28 (15_suppl), p.3588-3588

2010

Volltextzugriff (PDF)

DUSPs as markers of MEK/Erk activation in primary colorectal cancer

Journal of clinical oncology, 2009-05, Vol.27 (15_suppl), p.4064-4064

2009

Volltextzugriff (PDF)

The role of KRAS, BRAF, NRAS, and PIK3CA mutations as markers of resistance to cetuximab in chemorefractory metastatic colorectal cancer

Journal of clinical oncology, 2009-05, Vol.27 (15_suppl), p.4020-4020

2009

Volltextzugriff (PDF)

Use of amphiregulin and epiregulin mRNA expression in primary tumors to predict outcome in metastatic colorectal cancer treated with cetuximab

Journal of clinical oncology, 2009-05, Vol.27 (15_suppl), p.4019-4019

2009

Volltextzugriff (PDF)

Association between EGFR gene copy number and KRAS status and impact on outcome prediction in colorectal cancer patients treated with cetuximab

Journal of clinical oncology, 2008-05, Vol.26 (15_suppl), p.11093-11093

2008

Volltextzugriff (PDF)

Relationship of efficacy with KRAS status (wild type versus mutant) in patients with irinotecan-refractory metastatic colorectal cancer (mCRC), treated with irinotecan (q2w) and escalating doses of cetuximab (q1w): The EVEREST experience (preliminary data)

Journal of clinical oncology, 2008-05, Vol.26 (15_suppl), p.4001-4001

2008

Volltextzugriff (PDF)

Role of KRAS mutation in predicting response, progression-free survival, and overall survival in irinotecan-refractory patients treated with cetuximab plus irinotecan for a metastatic colorectal cancer: Analysis of 281 individual data from published series

Journal of clinical oncology, 2008-05, Vol.26 (15_suppl), p.4035-4035

2008

Volltextzugriff (PDF)

KRAS mutations preclude tumor shrinkage of colorectal cancers treated with cetuximab

Journal of clinical oncology, 2007-06, Vol.25 (18_suppl), p.4132-4132

2007

Volltextzugriff (PDF)

Outcome prediction to cetuximab in advanced colorectal cancer: Analysis of EGFR and HER2 gene copy number by fluorescence in situ hybridization

Journal of clinical oncology, 2007-06, Vol.25 (18_suppl), p.10569-10569

2007

Volltextzugriff (PDF)

P.197 Impact du génotypage de KRAS sur la réponse, la survie sans progression et la survie globale des patients réfractaires à l’irinotécan et traités par cetuximab plus irinotécan pour un cancer colorectal métastatique

Gastroentérologie clinique et biologique, 2009-03, Vol.33 (3), p.A147-A147

2009

Volltextzugriff (PDF)

Development and External Validation of a Model Predicting New‐Onset Chronic Uveitis at Different Disease Durations in Juvenile Idiopathic Arthritis

Arthritis & rheumatology (Hoboken, N.J.), 2023-02, Vol.75 (2), p.318-327

2023

Volltextzugriff (PDF)

1 – 25 von 49

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(47)
Mit Volltextzugriff
(47)

Publikationsform

Artikel
(48)
Buchkapitel
(1)

Sprache

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(22)
Science & Technology
(22)
Humans
(14)
Rheumatology
(14)
Arthritis
(12)
Patients
(9)
Pediatrics
(8)
Juvenile Idiopathic Arthritis
(7)
Biological And Medical Sciences
(6)
Epidemiology
(6)
Arthritis, Juvenile - Drug Therapy
(5)
Female
(5)
Oncology
(5)
Child
(4)
Drug Therapy
(4)
Gastroenterology. Liver. Pancreas. Abdomen
(4)
Hematology, Oncology And Palliative Medicine
(4)
Male
(4)
Medical Research
(4)
Medical Sciences
(4)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab

Radiological tumor size decrease at week 6 is a potent predictor of outcome in chemorefractory metastatic colorectal cancer treated with cetuximab (BOND trial)

Treatment of patients with newly diagnosed metastatic hormone sensitive prostate cancer (mHSPC) in Belgium: a real world data analysis

Changes in anticancer treatment plans in patients with solid cancer hospitalized with COVID-19: analysis of the nationwide BSMO-COVID registry providing lessons for the future

Treatment of Zenker’s diverticulum through a flexible endoscope with a transparent oblique-end hood attached to the tip and a monopolar forceps

6005 PIK3CA, BRAF and KRAS mutations and outcome prediction in chemorefractory metastatic colorectal cancer (mCRC) patients treated with EGFR targeting monoclonal antibodies (MoAbs): results of a European Consortium

Malnutrition prevalence in advanced cancer patients in Belgium

92 POSTER Amphiregulin and Epiregulin expression in primary colorectal cancer identifies a subgroup of patients that will respond to EGFR inhibition

98 POSTER DUSP4 expression level in colorectal primaries predicts overall survival benefit in Kras wild-type and Kras mutant colorectal cancer after treatment with cetuximab for metastatic disease

P19 Levels of amphiregulin and epiregulin expression correlate with overall survival in colorectal cancer treated with cetuximab

Potential Biomarkers for Response to Cetuximab in Patients with Metastatic Colorectal Cancer (MCRC). A Hellenic Cooperative Oncology Group Study

630 - Potential Biomarkers for Response to Cetuximab in Patients with Metastatic Colorectal Cancer (MCRC). A Hellenic Cooperative Oncology Group Study

P1.28 Dusp4 Expression as A Marker of Heterogeneous Signaling in Colorectal Cancer Patients

Use of tumor size decrease at 6 weeks (w) to predict response (OR), time to progression (TTP), and survival (OS) in chemorefractory metastatic colorectal cancer (cmCRC) treated with cetuximab (CTX) (BOND trial)

New insights to gene expression signatures from primary FFPE tumors for the prediction of response to cetuximab in KRAS and BRAF wild-type colorectal cancer (CRC)

DUSPs as markers of MEK/Erk activation in primary colorectal cancer

The role of KRAS, BRAF, NRAS, and PIK3CA mutations as markers of resistance to cetuximab in chemorefractory metastatic colorectal cancer

Use of amphiregulin and epiregulin mRNA expression in primary tumors to predict outcome in metastatic colorectal cancer treated with cetuximab

Association between EGFR gene copy number and KRAS status and impact on outcome prediction in colorectal cancer patients treated with cetuximab

Relationship of efficacy with KRAS status (wild type versus mutant) in patients with irinotecan-refractory metastatic colorectal cancer (mCRC), treated with irinotecan (q2w) and escalating doses of cetuximab (q1w): The EVEREST experience (preliminary data)

Role of KRAS mutation in predicting response, progression-free survival, and overall survival in irinotecan-refractory patients treated with cetuximab plus irinotecan for a metastatic colorectal cancer: Analysis of 281 individual data from published series

KRAS mutations preclude tumor shrinkage of colorectal cancers treated with cetuximab

Outcome prediction to cetuximab in advanced colorectal cancer: Analysis of EGFR and HER2 gene copy number by fluorescence in situ hybridization

P.197 Impact du génotypage de KRAS sur la réponse, la survie sans progression et la survie globale des patients réfractaires à l’irinotécan et traités par cetuximab plus irinotécan pour un cancer colorectal métastatique

Development and External Validation of a Model Predicting New‐Onset Chronic Uveitis at Different Disease Durations in Juvenile Idiopathic Arthritis

Suchergebnisse filtern